Read by QxMD icon Read

sct-1 cells

Wasil Jastaniah, Mohamed Bayoumy, Abdulrahman Alsultan, Saad Al Daama, Walid Ballourah, Faisal Al-Anzi, Omar Al Shareef, Reem Al Sudairy, Mohammed Burhan Abrar, Ibrahim Al Ghemlas
BACKGROUND: The outcome of childhood acute myeloid leukemia (AML) in first relapse (rAML) remains poor. Reported overall survival (OS) rates vary between high-income developed countries and those with fewer resources. The OS of rAML in high-income developing countries (HIDCs) has not been reported. PATIENTS AND MATERIALS: A multicenter study was performed in an HIDC. The outcome of patients with relapsed non-M3/non-Down syndrome AML was evaluated. Three-year OS was computed using the Kaplan-Meier method, and predictors of OS were analyzed using a Cox proportional hazards model...
September 12, 2018: Clinical Lymphoma, Myeloma & Leukemia
Patrice Chevallier, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Beatrice Mahé, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Anne Lok, Yannick Le Bris, Marie C Béné, Steven Le Gouill, Philippe Moreau, Thierry Guillaume
Background: The Baltimore reduced-intensity conditioning (RIC) regimen using high-dose post-transplant cyclophosphamide (PTCY) is considered as a standard of care for haploidentical allogeneic stem cell transplantation (allo-SCT). However, it is associated with relatively low survivals and high incidence of relapse, especially when considering myeloid malignancies. Results: This retrospective study included 36 adults (males n = 18; median age: 60.5 years old; haplodonors n = 27; matched donors n = 8) with myeloid malignancies transplanted between March 2014 and March 2017 at the University Hospital of Nantes...
September 11, 2018: Oncotarget
Gabriel Tremblay, Mike Dolph, Sachin Patel, Patricia Brandt, Anna Forsythe
Aims: Midostaurin (MIDO) has been proposed for the treatment of newly-diagnosed adult patients with FMS-like tyrosine kinase 3 mutation-positive (FLT3+) acute myeloid leukemia (AML) in combination with standard chemotherapy. The cost-effectiveness of MIDO and standard of care (SOC) followed by MIDO monotherapy was compared to SOC alone for newly-diagnosed FLT3+ AML in the UK. Methods: A partitioned survival model was developed from a UK public healthcare system perspective to compare the cost-effectiveness of MIDO plus SOC and SOC over a lifetime horizon...
2018: Cost Effectiveness and Resource Allocation: C/E
Jean Jacques Noubiap, Mazou N Temgoua, Ronni Tankeu, Joel Noutakdie Tochie, Ambroise Wonkam, Jean Joël Bigna
Background: Globally, sickle cell disease (SCD) is one of the most common haemoglobinopathy. Considered a public health problem, it leads to vessel occlusion, blood stasis and chronic activation of the coagulation system responsible for vaso-occlussive crises and venous thromboembolism (VTE) which may be fatal. Although contemporary observational studies suggest a relationship between SCD or sickle trait (SCT) and VTE, there is lack of a summary or meta-analysis data on this possible correlation...
2018: Thrombosis Journal
Hirohito Yamazaki
"The guidelines for the diagnosis and treatment of aplastic anemia (AA) in Japan" have recently been revised. Former stage 2 has been divided into stage 2a, which does not require red blood cell (RBC) transfusions, and stage 2b, which requires <2 units of RBC transfusions per month. In addition, the guidelines recommend treating stage 2b similar to stages 3 or higher severity. The standard immunosuppressive therapy for transfusion-dependent AA has been changed from ATG plus cyclosporine (CsA) to ATG+CsA+eltrombopag...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Francesco Gaudio, Patrizio Mazza, Angelo Michele Carella, Anna Mele, Giulia Palazzo, Giovanni Pisapia, Paola Carluccio, Domenico Pastore, Nicola Cascavilla, Giorgina Specchia, Vincenzo Pavone
BACKGROUND: Hodgkin lymphoma (HL) is a potentially curable disease, and modern therapy is expected to successfully cure more than 80% of the patients. However, patients progressing after intensive treatments, such as autologous stem cell transplantation (SCT), have a very poor outcome. Allogeneic SCT offers the only strategy with a curative potential for these patients. This study reports a retrospective multicenter experience of the Rete Ematologica Pugliese (REP) over the past 17 years, aiming to define the impact of each patient's disease and transplant-related characteristics on outcomes...
September 12, 2018: Clinical Lymphoma, Myeloma & Leukemia
Prachi Jain, Xin Tian, Stefan Cordes, Jinguo Chen, Caroline R Cantilena, Christian Bradley, Reema Panjwani, Fariba Chinian, Keyvan Keyvanfar, Minoo Battiwalla, Pawel Muranski, A John Barrett, Sawa Ito
Blockade of the T cell exhaustion marker PD-1 to re-energize the immune response is emerging as a promising cancer treatment. Relapse of hematological malignancy after allogeneic stem cell transplantation (allo-SCT) limits the success of this approach and PD-1 blockade may hold therapeutic promise. However, PD-1 expression and its relationship with post-transplant relapse is poorly described. Since the donor immunity is activated by allo-responses, PD-1 expression may differ from non-transplanted individuals and PD-1 blockade could risk graft-versus-host disease...
October 4, 2018: Biology of Blood and Marrow Transplantation
Niels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, Edo Vellenga, Sandra Croockewit, Marie José Kersten, Peter A von dem Borne, Paula Ypma, Ron Schaafsma, Okke de Weerdt, Saskia K Klein, Michel Delforge, Mark-David Levin, Gerard M Bos, Kon-Siong G Jie, Harm Sinnige, Jules Llm Coenen, Esther G de Waal, Sonja Zweegman, Pieter Sonneveld, Henk M Lokhorst
BACKGROUND: In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of follow-up, by comparison with regimens containing classical cytotoxic drugs. In this follow-up analysis, we aimed to determine the long-term effects of thalidomide in induction and maintenance therapy in multiple myeloma...
October 2018: Lancet Haematology
So Hyun Nam, Min Jeng Cho, Dae Yeon Kim, Seong Chul Kim
BACKGROUND: Alpha-fetoprotein (AFP) is useful as a tumor marker for sacrococcygeal teratoma (SCT). We investigated the half-life of AFP in SCT. METHODS: Neonates who underwent surgical treatment for SCT between 1997 and 2016 were included in the study, whereas patients who died before or after surgery or had malignant germ cell tumors were excluded. RESULTS: Fifty-five non-recurrent SCT patients (M:F = 18:37) were enrolled. They underwent surgery on average 7...
September 2, 2018: Journal of Pediatric Surgery
Tania Jain, Mohamad Bassam Sonbol, Belal Firwana, Kantha R Kolla, Diana Almader-Douglas, Jeanne Palmer, Rafael Fonseca
Autologous stem cell transplantation (SCT) is the standard of care for all transplant eligible patients diagnosed with multiple myeloma (MM). Various studies have compared clinical outcomes with frontline SCT ("Early SCT") versus standard dose therapy (SDT) alone, with or without salvage SCT ("SDT/ late SCT"). In this meta-analysis, we compare overall survival (OS) and progression free survival (PFS) outcomes with these two treatment approaches. Twelve studies were identified, including 3,633 patients, of which 1,811 received early SCT while 1,822 received SDT/ late SCT...
September 20, 2018: Biology of Blood and Marrow Transplantation
Oleg V Kolupaev, Trisha A Dant, Hemamalini Bommiasamy, Danny W Bruce, Kenneth A Fowler, Stephen L Tilley, Karen P McKinnon, Stefanie Sarantopoulos, Bruce R Blazar, James M Coghill, Jonathan S Serody
Chronic graft-versus-host disease (cGVHD) causes significant morbidity and mortality in patients after allogeneic bone marrow (BM) or stem cell transplantation (allo-SCT). Recent work has indicated that both T and B lymphocytes play an important role in the pathophysiology of cGVHD. Previously, our group showed a critical role for the germinal center response in the function of B cells using a bronchiolitis obliterans (BO) model of cGVHD. Here, we demonstrated for the first time that cGVHD is associated with severe defects in the generation of BM B lymphoid and uncommitted common lymphoid progenitor cells...
September 25, 2018: Blood Advances
Jennifer Brite, Tracy McMillen, Elizabeth Robilotti, Janet Sun, Hoi Yan Chow, Frederic Stell, Susan K Seo, Donna McKenna, Janet Eagan, Marisa Montecalvo, Donald Chen, Kent Sepkowitz, Mini Kamboj
OBJECTIVE: To determine the effectiveness of ultraviolet (UV) environmental disinfection system on rates of hospital-acquired vancomycin-resistant enterococcus (VRE) and Clostridium difficile. DESIGN: Using active surveillance and an interrupted time-series design, hospital-acquired acquisition of VRE and C. difficile on a bone marrow transplant (BMT) unit were examined before and after implementation of terminal disinfection with UV on all rooms regardless of isolation status of patients...
September 18, 2018: Infection Control and Hospital Epidemiology
Maximilian Christopeit, Myriam Labopin, Norbert-Claude Gorin, Francesco Saraceni, Jakob Passweg, Edouard Forcade, Johan Maertens, Maria Teresa Van Lint, Alberto Bosi, Dietger Niederwieser, Gerhard Ehninger, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
Patients with acute myeloid leukemia (AML) who relapse after autologous stem cell transplantation (ASCT) can be rescued by allogeneic SCT. We identified 537 adult patients with AML allografted in second complete remission (CR2) or first relapse after ASCT in the European Society for Blood and Marrow Transplantation (EBMT) registry and. At 3 years post allograft, leukemia free survival (LFS) was 31.4% [95%CI 27.3-35.6], overall survival (OS) 39.5% [95%CI 35.1-43.9], relapse incidence (RI) 34.6% [95%CI 30.4-38...
September 14, 2018: American Journal of Hematology
Ken-Ichi Matsuoka
Post allogeneic hematopoietic stem cell transplantation, CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) play a central role in the maintenance of self-tolerance and immune homeostasis. In recent years, various immune-modulating agents, including cyclophosphamide, mogamulizumab, and antibodies to inhibitory co-stimulating molecules (CTLA-4 and PD-1), have been used to control donor-derived immunity or host-tumor burden during the peritransplant period; however, the underlying impact of these agents on Treg homeostasis is yet to be characterized...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Tal Schechter, Evelio Perez-Albuerne, Tiffany F Lin, Meredith S Irwin, Mohammed Essa, Ami V Desai, Haydar Frangoul, Gregory Yanik, L Lee Dupuis, David Jacobsohn, Morris Kletzel, Mark Ranalli, Sandeep Soni, Alix E Seif, Stephan Grupp, Christopher C Dvorak
Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy. Data regarding the patients, SCT characteristics, busulfan steady-state concentrations, incidence of VOD, and survival were evaluated...
September 4, 2018: Bone Marrow Transplantation
L M Liu, Y M Zhang, H F Zhou, Q Y Wang, H Y Qiu, X W Tang, Y Han, C C Fu, Z M Jin, A N Sun, M Miao, D P Wu
Objective: To evaluate the outcome of combination of haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) with an unrelated cord blood unit for severe aplastic anemia (SAA). Methods: The clinical data of 127 SAA patients [including 74 male and 53 female patients, 65 very severe aplastic anemia (vSAA), the median age as 23.5(3-54) years] received HID-HSCT from September 2011 to April 2017 were analyzed retrospectively. The median interval from SAA diagnosis to transplantation was 2 (0.5-180) months...
August 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Jan Walewski, Andrzej Hellmann, Noppadol Siritanaratkul, Guner Hayri Ozsan, Muhit Ozcan, Suporn Chuncharunee, Ai Sim Goh, Wojciech Jurczak, Jan Koren, Ewa Paszkiewicz-Kozik, Bingxia Wang, Shalini Singh, Dirk Huebner, Andreas Engert, Bastian von Tresckow
Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks) in 60 patients (aged ≥18 years) with CD30-positive relapsed/refractory HL, a history of ≥1 prior systemic chemotherapy regimen, who were considered unsuitable for SCT/multi-agent chemotherapy. Primary endpoint was overall response rate (ORR) per independent review facility (IRF)...
August 30, 2018: British Journal of Haematology
Jaakko Valtola, Raija Silvennoinen, Antti Ropponen, Timo Siitonen, Marjaana Säily, Marja Sankelo, Mervi Putkonen, Anu Partanen, Marja Pyörälä, Eeva-Riitta Savolainen, Pentti Mäntymaa, Jukka Pelkonen, Esa Jantunen, Ville Varmavuo
The composition of autologous blood grafts after cryopreservation, post-transplant hematological recovery up to 1 year and immune recovery up to 6 months as well as outcome was analyzed in 87 patients with multiple myeloma (MM). The patients receiving added plerixafor due to poor mobilization (11%) were compared to those mobilized with G-CSF or cyclophosphamide (CY) plus G-CSF. The use of plerixafor was found to significantly affect the graft composition as there was a significantly higher proportion of the more primitive CD34+ cells, higher number of T and B lymphocytes as well as NK cells in the grafts of patients who received also plerixafor...
August 30, 2018: Leukemia & Lymphoma
Eduardo Rodríguez-Arbolí, Francisco José Márquez-Malaver, Nancy Rodríguez-Torres, Teresa Caballero-Velázquez, Virginia Escamilla-Gómez, Cristina Calderón-Cabrera, José Francisco Falantes-González, María Solé-Rodríguez, Patricia García-Ramírez, María Moya-Arnao, Enric Carreras, Ildefonso Espigado-Tocino, José Antonio Pérez-Simón
Clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-SCT) from unrelated donors (URDs) approach those of matched related donor (MRD) transplants in patients with acute myeloid leukemia (AML). Yet, available data fail to account for differences in pretransplantation outcomes between these donor selection strategies. In this regard, URD allo-HSCT is associated with longer waiting times to transplantation, potentially resulting in higher probabilities of failure to reach transplant...
August 25, 2018: Biology of Blood and Marrow Transplantation
Olatunde P Olabode, Olawale M Akinlade, Abiola S Babatunde, Musbau I Abdulazeez, Sikiru A Biliaminu, Adewumi O Oyabambi, Victoria A Olatunji, Ayodele O Soladoye, Lawrence A Olatunji
We hypothesised that TG/HDL-C ratio and PAI-1 would be associated with high pulse pressure (PP) in young adults with sickle cell trait (SCT) and sickle cell disease (SCD). We compared the clinical, biochemical, and cardiometabolic parameters among individuals with normal genotype (HbAA; n = 60), SCT (HbAS; n = 60), and SCD (HbSS; n = 60), all in steady state. Using multivariate linear regression analysis, high PP was positively related to TG/HDL-C ratio in SCT (β = 0.307; p = .014) and PAI-1 (β = 0...
August 25, 2018: Archives of Physiology and Biochemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"